

Editor's note: This English translation was done by a third party. The original digital story can be accessed [here](#).

Hair loss Propecia Disappears from the Market
By Charlotte Demarty

The originator of finasteride 1 mg, Propecia, quits the market, giving way to its generics. Additionally, all boxes of finasteride 1 mg now display a warning message about sexual and psychiatric adverse reactions.

The Organon Laboratory has stopped marketing Propecia 1 mg (84 tablets), effective January 31, 2023, as well as that of Propecia 1 mg (28 tablets), since April 27, 2023.

"If necessary, the pharmacist will dispense one of the generic versions" of finasteride (Arrow Lab, Bailleul, Biogaran, Cristers, EG, Sandoz, Teva, Viatris), which, at this low dosage of 1 mg, is used to treat hair loss in men, according to the National Agency for Safety of Medicines and Health Products (ANSM).

In addition to this disappearance from the market, remember that ANSM implemented, on December 1, 2022, a measure to inform about the risks associated with finasteride 1 mg.

Since that date, and no later than April 28, 2023, all boxes of finasteride 1 mg have a red box on their main side (front side) indicating that sexual and/or psychiatric adverse effects may occur during and after treatment, accompanied by a QR code that refers to the ANSM's dossier page "Finasteride 1 mg and hair loss."